Publication: New determinates of disease progression and outcome in metastatic ovarian carcinoma
Loading...
Date
2010
Authors
Davidson, Ben ; Reich, Reuven ; Trope, Claes G. ; Wang, Tian-Li ; Shih, Ie-Ming
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Ovarian cancer is the most lethal
gynecologic malignancy. This is attributed to frequent
presentation at late stage, when the tumor has
metastasized, as well as to development of
chemotherapy resistance along tumor progression.
Patients with advanced-stage ovarian carcinoma have
widespread intraperitoneal metastases, including the
formation of malignant serous effusions within the
peritoneal cavity. Pleural effusions constitute the most
frequent site of distant metastasis (FIGO stage IV
disease). Unlike the majority of solid tumors,
particularly at the primary site, cancer cells in effusions
are not amenable to surgical removal, and failure in their
eradication is one of the main causes of treatment
failure. Our research in recent years has demonstrated
that a large number of cancer-associated molecules are
differentially expressed in effusions compared to
primary carcinomas and solid metastases. We have
additionally observed that expression of several of these
molecules differs between primary diagnosis (prechemotherapy)
and disease recurrence (postchemotherapy)
specimens, and that they are significantly
associated with response to chemotherapy and patient
survival. These observations are thought to be related to
disease progression, as well as to the unique
microenvironment of effusions, and may have impact on
the selection of targeted therapy in this cancer. This
review discusses our recent observations with respect to
the biology of ovarian carcinoma cells in effusions, and
focuses on the clinical role of tumor-associated
molecules at this anatomic site.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.